Arena Pharmaceuticals, Inc. (ARNA)
-NasdaqGS | Prev Close: | 7.99 |
|---|
| Open: | N/A |
|---|
| Bid: | 7.99 x 1000 |
|---|
| Ask: | 8.08 x 500 |
|---|
| 1y Target Est: | 8.36 |
|---|
| Beta: | -0.54 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 5.78 - 13.50 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 5,350,210 |
|---|
| Market Cap: | 1.74B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.37 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Arena Pharmaceuticals - Out To Launch Or Out To Lunch?at Seeking Alpha(Wed, 15:19 SGT)
- Nasdaq stocks posting largest percentage decreasesAP(Wed, 08:50 SGT)
- The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Doesat Seeking Alpha(Tue, 21 May)
- The 9 Most Obese Countries in the Worldat Motley Fool(Tue, 21 May)
- Arena NOLs Will Come Into Play Soonat Seeking Alpha(Mon, 20 May)
- Vivus Taps Into More Cashat Seeking Alpha(Sun, 19 May)
- 25 Belt-Busting Obesity Factsat Motley Fool(Sat, 18 May)
- ARENA PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Sat, 18 May)
- Ahead of the Bell: Arena Pharma price targets fallAP(Fri, 3 May)
- Arena shares plunge after disappointing 1Q resultsAP(Fri, 3 May)
- Vivus Unveils Qsymia Study ResultsZacks(Fri, 8 Feb)
- Update on Orexigen's ContraveZacks(Fri, 11 Jan)
- Takeda Terminates Amylin AgreementZacks(Mon, 31 Dec)
- Arena Cuts Loss, Affirms Sales ViewZacks(Fri, 9 Nov)
- Vivus Misses 3Q EstimatesZacks(Fri, 9 Nov)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 62.66 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.14 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.12 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | -2.29 |
|---|
Business Summary
Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory,...
View More